Wegovy side effects and your eyes: what's known, what's uncertain

Step 1: understand what the prescribing information actually says

The semaglutide SmPC and Patient Information Leaflet list blurred vision as an uncommon side effect, meaning it may affect up to 1 in 100 people. For most, this is mild and transient, often linked to early blood-sugar changes rather than direct harm to the eye itself. The NHS semaglutide medicines page confirms this, grouping it alongside the more familiar gastrointestinal effects that tend to settle in the first few weeks.

What changed the conversation was a 2024 observational study published in JAMA Ophthalmology, which reported a statistically higher rate of NAION (non-arteritic anterior ischaemic optic neuropathy) among semaglutide users compared with people on other weight-loss medicines. NAION occurs when blood flow to the optic nerve is suddenly reduced. It typically presents as painless vision loss in one eye and can be permanent. The study did not prove causation, and absolute numbers remain small, but it was significant enough to prompt wider scrutiny and ongoing regulatory review.

It is also worth noting that the Wegovy licence covers weight management; the diabetic retinopathy complication risk described below applies primarily in a diabetes-treatment context, but anyone with a history of retinopathy should discuss it before starting. Our Wegovy treatment overview sets out the full licensed indications.

Step 2: know which people carry a higher background risk

NAION is not a random event. Certain structural and vascular characteristics increase a person's baseline risk independent of any medicine. A small optic disc-to-cup ratio (sometimes called a "disc at risk"), a history of high blood pressure, diabetes, obstructive sleep apnoea, or elevated cholesterol are all associated with higher NAION risk in the general population.

For people with type 2 diabetes starting semaglutide, a separate concern applies: rapid improvement in blood-glucose control can, in a minority of cases, temporarily worsen diabetic retinopathy. This is a recognised phenomenon with intensive glucose-lowering therapy more broadly; it is not unique to Wegovy, but it means anyone with existing retinopathy should have an eye-health discussion with their diabetes team before beginning treatment. Our page on semaglutide eye side effects covers the evidence around this risk in more detail, including what the clinical studies found.

None of this means these groups cannot use Wegovy. It means the prescriber needs the full picture. At nume, every consultation is read by a named, GPhC-registered prescriber, a real clinician who reviews your health history, not a checklist run through software. That review is where these individual factors get weighed.

Step 3: recognise symptoms that need prompt medical attention

Most people on Wegovy will not experience any eye symptoms at all. For those who do, the level of urgency matters.

Mild, transient blurring in the early weeks (especially if you have recently had a dose increase) is relatively common and usually self-limiting. It is still worth mentioning at your next clinical review, but it is not an emergency. You can raise it with the aftercare team if you want guidance sooner.

These symptoms, by contrast, need same-day medical assessment: sudden loss of vision in one eye (even partial), a shadow or curtain across your visual field, double vision that comes on quickly, or any vision change accompanied by eye pain. Do not wait for your next scheduled review. Call 111, attend an eye casualty department, or go to A&E depending on severity. Wegovy should be paused pending assessment.

The MHRA Yellow Card scheme allows patients and clinicians to report suspected side effects; reporting eye symptoms helps regulators build a clearer picture of how common they are and whether patterns emerge across the semaglutide-using population. It takes about ten minutes and genuinely contributes to medicine safety.

Step 4: what to discuss at consultation before you start

If you have any existing eye condition (glaucoma, macular degeneration, a history of NAION or retinal vein occlusion, or established diabetic retinopathy) raise it explicitly when filling in your consultation. The prescriber will factor it into their assessment. This is not a reason to avoid Wegovy automatically; it is information that shapes a safer, more personalised decision.

People who wear glasses or contact lenses and notice a prescription shift in the early months of treatment often ask whether semaglutide changed their vision. Significant weight loss can alter corneal curvature slightly, which sometimes shifts refraction. That is different from a pathological eye side effect and is something your optician can assess. If you want a thorough breakdown of what has been reported specifically with the weight-management licence, our page on Wegovy eye side effects brings together the clinical findings and what they mean in practice, and our dedicated page on how Wegovy may affect eye sight explores the vision-specific concerns in further depth. A useful starting point if you want to explore the wider evidence on semaglutide and the eyes is our page on semaglutide eye side effects, which covers the research landscape in more depth.

Wegovy is a prescription-only medicine, and suitability for treatment depends on a full clinical assessment. If you are considering it, our prescribers discuss both the potential benefits and side effects, including eye-related ones, as part of every consultation. You can explore the treatment options and start a free consultation whenever you are ready. There is no obligation, and the assessment is free.